首页> 美国卫生研究院文献>Saudi Pharmaceutical Journal : SPJ >Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori
【2h】

Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori

机译:用于消灭幽门螺杆菌的胃滞留左氧氟沙星漂浮微型胶囊系统的设计和评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastroretentive levofloxacin (LVF) floating mini-tablets for the eradication of Helicobacter pylori (H. pylori) were prepared using the matrix forming polymer hydroxypropyl methylcellulose (HPMC K100M), alone or with Carbopol 940P in different ratios by wet granulation technique. Buoyancy of mini-tablets was achieved by an addition of an effervescent mixture consisting of sodium bicarbonate and anhydrous citric acid to some formulations. The prepared mini-tablets were evaluated for weight variation, thickness, friability, hardness, drug content, in vitro buoyancy, water uptake and in vitro release. The optimized formula was subjected to further studies: FT-IR, DSC analysis and in vivo examination in healthy volunteers. The prepared mini-tablets exhibited satisfactory physicochemical characteristics. Incorporation of gas-generating agent improved the floating parameters. HPMC K100M mini-tablet formulation (F1) offered the best controlled drug release (>8 h) along with floating lag time <1 s and total floating time >24 h. The obtained DSC thermograms and FT-IR charts indicated that there is no positive evidence for the interaction between LVF and ingredients of the optimized formula. The in vivo test confirmed the success of the optimized formula F1 in being retained in the stomach of the volunteers for more than 4 h. LVF floating mini-tablets based on HPMC K100M is a promising formulation for eradication of H. pylori.
机译:用基质形成的聚合物羟丙基甲基纤维素(HPMC K100M)单独或与Carbopol 940P通过不同比例的湿法制粒技术制备用于消灭幽门螺杆菌(H. pylori)的胃滞留左氧氟沙星(LVF)漂浮微型片剂。通过向某些配方中添加由碳酸氢钠和无水柠檬酸组成的泡腾混合物,可以达到微型药片的浮力。评估所制备的迷你片剂的重量变化,厚度,易碎性,硬度,药物含量,体外浮力,吸水率和体外释放。对优化后的配方进行了进一步的研究:FT-IR,DSC分析和健康志愿者的体内检查。制备的微型片剂表现出令人满意的理化特性。气体发生剂的加入改善了漂浮参数。 HPMC K100M微型片剂配方(F1)具有最佳的药物释放控制(> 8小时),漂浮滞后时间<1秒,总漂浮时间> 24小时。所获得的DSC热谱图和FT-IR图表明,没有LVF与优化配方成分之间相互作用的积极证据。体内试验证实了优化的配方F1在志愿者的胃中保留超过4小时的成功。基于HPMC K100M的LVF漂浮微型片剂是用于根除幽门螺杆菌的有前途的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号